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3SUMMARYBrown adipose tissue uptake of glucose and fatty acids is very high during non-shivering thermogenesis. Adrenergic stimulation markedly increases glucose uptake, de
novo lipogenesis and FA oxidation simultaneously. The mechanism that enables thisconcerted response has hitherto been unknown. Here we find that in a brown adipocytecell line (IMBAT-1) acute inhibition and longer-term knockdown of DGAT2 links theincreased de novo synthesis of fatty acids from glucose to a pool of TG which issimultaneously hydrolysed, providing FA for mitochondrial oxidation. DGAT1 does notcontribute to this pathway, but uses exogenous FA and glycerol to synthesise a pool of TGfrom which the labelling of CO2 is very low; DGAT2 also contributes to it. The DGAT2-dependent channelling of 14C from glucose into TG and CO2   was reproduced in  β3-agonist-stimulated primary brown adipocytes. Knockdown of DGAT2 in IMBAT-1affected the mRNA levels of several genes important in FA activation and esterification.
Therefore, in β3-agonist activated brown adipocytes, DGAT2 specifically enables channelling of de novo synthesised FA into a rapidly mobilised pool of TG which issimultaneously hydrolysed to provide substrates for mitochondrial fatty acid oxidation.
4INTRODUCTIONThe diacylglycerol acytransferases, DGAT1 and DGAT2 catalyse the last, dedicatedstep of triacylglercerol (TG) synthesis. Although they catalyse the same reaction (withminor differences in substrate preferences) and are co-expressed in all the cell types inwhich they occur, they are functionally non-redundant. In particular, in the liver, DGAT2is specialised for the formation of TG from de novo synthesised fatty acids and newlyformed diglycerides (DG) thus acting upstream of DGAT1 in the de novo synthesis of TG(1). This renders DGAT2 essentially rate-limiting for the de novo formation of TG in theliver (2), and is consistent with the observation that the liver of mice lacking a keyenzyme of the glycerol-3-P pathway (Gpat 1-/-) is depleted of TG, and is unable to esterify
de novo synthesised FA to TG (3). Although DGAT2 also participates in the maintenanceof the TG pool(s) in lipid droplets through the lipolysis-reesterification cycling that occursbetween TG and DG (4), the esterification between preformed FA and partial glyceridesis primarily performed by DGAT1 in HepG2 cells (1) and in murine liver (5). This isconsistent with the observations that Dgat 1-/- and Dgat 2-/- mice have very differentphenotypes, with Dgat 1-/- animals having a metabolically favourable phenotype(including lower plasma and tissue TG) (6), whereas Dgat 2-/- animals dying withinseveral hours after birth, and being devoid of TG (lipopenic) (7). This specialisation ofhepatic DGAT2 for the utilization of de novo synthesised fatty acids (FA) is readilyrationalised in view of the role of the liver in integrating glycaemia, triglyceridaemia andhepatic TG content, and accommodating large fluxes of glucose metabolism, de novolipogenesis (DNL) and TG synthesis/secretion that it accommodates (2). However, thewider applicability, to other tissues and conditions, of this functional specialization ofDGAT2 remains to be determined (8,9).Brown adipose tissue (BAT) is another tissue that, like the liver, clears largeamounts of both glucose and FA (either non-esterified or as products of lipoprotein lipaseaction on triglyceride-rich lipoproteins) from the circulation (10). The very high rates ofuptake have been suggested to play a role in the regulation of glycaemia andtriglyceridaemia (11-13). During cold exposure, BAT has the highest rate of glucoseuptake and lipogenesis when compared to white adipose tissue (WAT) and the liver (14).
BAT glucose metabolism is independent of insulin but, during   β-adrenergic stimulation, 
5is stimulated by an increase in GLUT1 expression (via cAMP) and translocation to theplasma membrane, mediated through mTORC2 (15,16). Although glucose makes arelatively minor direct contribution (<20%) towards thermogenesis (through glycolysisand oxidation of pyruvate) (17,18), the contribution through oxidation of FA synthesised
de novo from glucose and other lipogenic substrates (e.g. lactate (19)) could beconsiderably larger (13) . Indeed, when non-shivering thermogenesis is maximallystimulated, BAT can account for 33% of whole-body lipogenesis, and newly synthesisedFAs make a significant contribution towards the thermogenic capacity of BAT in adultrodents (14). The very substantial lipogenic capacity of BAT (20) and its activation in
vivo upon cold-exposure of animals (21,22) are accompanied by increased nuclearexpression of SREBP1 and elevated gene expression of lipogenic and FA-elongationenzymes when mice are maintained at sub-thermoneutral temperatures (23).Therefore, in view of the very high lipogenic potential of BAT (10,24,25), thecontribution of de novo synthesised FA towards BAT thermogenesis may be substantial(13,26). FA, whether provided exogenously or synthesised de novo from glucose, activateUCP1 (by over-riding the inhibitory action of purine nucleotides on the protein), andprovide the ultimate substrate for uncoupled respiration in brown adipocytes (27).Glucose is also required to form glycerol-3-P for the (re)synthesis of TG from FA.Therefore, like the liver, BAT has to integrate large fluxes of glucose and fatty acidmetabolism, and may be a tissue in which the distinctive functions of DGAT1 and DGAT2may be important in directing different FA pools towards specific pathways duringadrenergic stimulation, when glucose uptake, de novo lipogenesis (DNL) and TG lipolysisare all coordinately activated (21,22,28). Expression profiling of mouse tissues, indicatesthat DGAT2 is expressed in BAT judging by the high level of its mRNA expressed in thetissue (29) and that its expression is increased (more than that of DGAT1) in BAT of cold-acclimated rodents (30). Therefore, in the present study, we have investigated the rolesof DGAT1 and DGAT2 in the metabolism of glucose and de novo synthesised FA, comparedto that of exogenous fatty acids in a brown adipocyte cell line (IMBAT-1) and in mouseprimary brown adipocytes. We identified a specific role for DGAT2 in linking glucoseuptake and DNL to the formation of TG which acts directlyde novo as a source of FA foroxidation, independently from the uptake and metabolism of extracellular FA.
6MATERIALS AND METHODS
Preparation and culture of primary brown adipocytesMouse primary brown adipocytes were prepared from the stromal fractionresulting from the collagenase digestion of inter-scapular brown adipose tissue obtainedfrom 4-week old mice. The stromal fraction was suspended in DMEM10, filtered through
a 40μm strainer, and cells plated in T25 flasks. The cells were allowed to expand until 80-90% confluent with regular replacement of media. After trypsinization and resuspensionin DMEM10 medium 5 x 104cells/well of 12-well plate were then plated and allowed toreach 100% confluence. Differentiation was induced by addition of medium containing
insulin (1μg/ml), IBMX (250uM), triiodothyronine, T3 (1nM), indomethacin (30μM), 
rosiglitazone (2μM) and dexamethasone (0.5μM). After 96h, during which the medium was replenished once, the cells were switched to maintenance medium (DMEM10medium supplemented with insulin, T3 and rosiglitazone only). After a further 48h, thecells were switched to a medium which contained the same concentrations of insulin andT3, but from which rosiglitazone was omitted. After a further 48h the medium waschanged to DMEM10, and the cells were used for experimental treatments.
Generation, differentiation and culture of IMBAT-1 cellsThe immortalised brown adipocyte cell line (IMBAT-1) was generated asdescribed previously (31). Briefly, preadipocytes isolated from murine interscapularbrown adipose tissue were immortalized by retroviral-mediated expression oftemperature-sensitive SV40 large T-antigen H-2kb-tsA58. Cells were cultured in DMEM-F12 medium (20mM D glucose) supplemented with 10% foetal bovine serum (FBS), 1%
L-glutamine, 1% Penicillin/streptomycin, Amphotericin B and 50μg/ml of G418 at 33°C in 5% CO2 and 95% air- water saturated atmosphere. Unless specified otherwise, cellswere passaged and harvested after treatment with 0.25% trypsin and 0.02% EDTA. Fordifferentiation to mature adipocytes, pre-adipocytes were plated onto gelatine-coated
plates and cultured until confluent. Induction medium containing 7.5mM glucose, 1μg/ml 
insulin, 250nM dexamethasone, 0.5mM IBMX, 1nM triidothyronine (T3) and 125μM Indomethacin was added for 48 hours at 37°C. Cells were then maintained in 7.5mM
glucose medium containing 1nM T3 and 1μg insulin /ml for 5 days at 37°C. Unless 
7otherwise stated, all experiments were performed on day 7 of differentiation or after afurther 72h treatment with siRNA. The experimental incubation medium was DMEM-F12medium containing 7.5mM D-glucose, 10% fetal bovine serum, 1% L-glutamine, 1%penicillin/streptomycin, 1mM L-carnitine, 0.75mM oleate with 0.25% BSA and 0.75mMglycerol.
SiRNA-mediated knockdown of DGAT1 or DGAT2Transfections were carried out on the day 7 of differentiation using SmartpoolsiRNA, designed by the manufacturers for DGAT1 and DGAT2, and transfection reagentlipofectamine RNAiMax, following the manufacturer’s instructions. Differentiatedadipocytes were dissociated with trypsin/EDTA followed by addition of DMEM/F12 with
10% FBS. Mixtures of transfection reagents, OptiMEM medium, 10μM siRNA-DGAT1 or 
10μM siRNA-DGAT2 or 10μM siRNA-control were incubated at room temperature for 25 min. They were then added to the dissociated cells along with antibiotic-free DMEM-F12medium (7.5mM glucose). Control cells were treated with scrambled siRNA. Media werechanged after 24 hours and cells were cultured for further 48 hours at 37°C inmaintenance medium. Preliminary experiments established that optimal knockdownswere achieved after 72h of siRNA treatment.
Measurement of the incorporation of 14C-glucose label into CO2 and cellular TGIMBAT-1 or primary brown adipocytes cells plated in gelatine-coated 6-wellplates containing 7.5mM glucose medium were incubated for 2h in the presence or
absence of the β3-adrenergic agonist CL (10μM) before the addition of label to start themeasurements. Preliminary experiments established the incorporation of [U-14C]-glucose into labelled products was linear for 2h and this period was used routinely when[U-14C]-glucose incorporation was studied. Where indicated, oleate or palmitate (0.75mMplus 0.25% albumin) and glycerol (0.75mM) were added to the incubations. Whenincorporation of label from 1-[14C]-oleate, U-[14C]-palmitate or 2-[3H]-glycerol wasmeasured, the labelling period was 1h to ensure linearity of incorporation into TG. In oneseries of experiments labelling with exogenous 1-[14C]-oleate was extended to 8h tomonitor the release of 14CO2. When effects of DGAT1 or DGAT2 inhibition were studied,the appropriate inhibitors were added 30 min before the start of the incubations with thelabel. Where indicated, etomoxir (80 µM) was added 30 min before the start of the
8experimental period by addition U-14C-glucose label. Lipolysis was inhibited by addition
of tetrahydrolipstatin (THL, 200μM) or Atglistatin (10μM) at the same time as the addition of CL i.e. 2 hours before addition of U-14C-glucose label.
Measurement of 14CO2 labellingFormation of 14CO2 after incubation of cells with labelled substrates for therequired period of time was measured by transferring 1 ml of the incubation medium toa 20-ml glass conical flask containing a 0.5-ml Fisher centre well holding filter paper to
which 400μl of benzethonium hydroxide had been added  (32). The flask was stoppered and 1.0 ml of 1 M H2SO4 was injected through the rubber stopper. The flasks were shakenfor 60 min at 37°C to allow the liberated 14CO2 to be absorbed by the benzethoniumhydroxide, after which the radioactivity associated with the contents of the centre-wellwas quantified using a liquid scintillation counter.
Measurement of incorporation of label into TGAt the end of the incubation period, the cells were washed with cold PBS, and totallipids were extracted from them using a chloroform/methanol mixture (2:1 v/v) (33).The chloroform layer was aspirated into a glass tube and dried under a stream of N2 gas.
The dried material was re-solubilized in chloroform (500μl) and the entire volume was applied onto a TLC plate coated with Silica Gel 60 for separation of the radioactivetriglyceride product, using hexane/diethyl ether/formic acid (70:30:1, v/v/v) as themobile phase. A TG-standard (tripalmitin) was used to identify the position of the TGband visualized using iodine vapour. The radioactivity associated with each band wasquantified after scraping into scintillation vials, addition of scintillant (Ultima GoldTM,Perkin Elmer) and measuring the associated radioactivity using a scintillation counter.Saponification of the total lipids was performed as described in (34) with minormodifications. The cellular total lipid extract were dried and dissolved in 0.75ml of 30%KOH and heated at 70°C for 10 min. An equal volume of 95% ethanol was then added andthe mixture was heated at 70 °C for 2 hours. After cooling, the aqueous fraction wasacidified with 3M HCl and extracted thrice with light petroleum. The organic fraction wasevaporated, re-dissolved in 1ml of light petroleum, transferred to scintillation vial andquantified as the TG-acyl fraction. The remaining aqueous fraction contained the TG-
9glyceryl fraction; 0.5ml aliquot of this sample was taken and measured for radioactivityusing scintillation counter.
Real time PCR quantitation of mRNA expressionTotal RNA was extracted from IMBAT-1 cells using TRIzol reagent. cDNA wasprepared using reverse transcription. Briefly RNA (1ug) was mixed with oligodT (1µl) ina final volume of 12 µl by adding RNAse free water. Samples were heated at 70°C for 5min before chilling on ice. Subsequently, 8µl of mixture containing RNAse inhibitor (10U/µl), dNTPs (10 mM), Bioscript reverse transcriptase and RNAse free water were addedto each sample. Samples were heated at 40 °C for 60 min and the reaction was stoppedby heating to 70 °C for 10min. The cDNA formed was mixed with 180µl of nuclease-freewater and stored at -20°C. Samples were thawed only once before quantification. Reversetranscription (RT-PCR) was performed using SYBR green dye and expression for all the
samples (n ≥ 3) was calculated by using the DCt method, incorporating the efficiencies of each primer pair. The variances of input cDNA were normalised against the levels of threehousekeeping genes; L19, B-actin and 36B4. Melting curve analysis confirmedamplification specificity. The primers used are detailed in Table S1 of the supplementarymaterial.
Statistical analysesDifferences between means for independent groups of data were analysed by ANOVAfollowed by the post hoc Tukey test.
MaterialsDulbecco’s Modified Eagle’s Medium DMEM10, DMEMF12, etomoxir sodium salt,CL, L-carnitine, benzethonium hydroxide, light petroleum (bp: 40-60 °C), glyceryltripalmitate, sodium oleate, insulin, IBMX, Indomethacin, and 3,3’5-triiodo-L-thyaminewere purchased from Sigma-Aldrich. TLC-pre-coated plates, 10ml conical flasks withcentre wells, lipofectamine, and RNAiMax were purchased from Fischer scientific.Rosiglitazone was from Cayman Chemical. Radiolabelled [U-14C]-glucose (specificactivity 250-360mCi/mmol), [1-14C] Oleic acid (specific activity: 40-60mCi/mmol) and[2-3H] glycerol (specific activity 0.5-1.0 Ci/mmol) was purchased from Perkin Elmer LAS(UK). ON-TARGETplus Mouse Dgat1 smartpool siRNA, ON-TARGETplus Mouse Dgat2
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smartpool siRNA and ON-TARGETplus non-targeting siRNA were purchased from GEHealthcare UK. Of the three inhibitors of DGAT activity used, DGAT1iB (cis-4-{3-fluoro-4-[({5-[(4-fluorophenyl)amino]-1,3,4-oxadiazol-2-yl}carbonyl)-amino]phenoxy}cyclohexane carboxylic acid) and DGAT2-iC (N-(4,5-dihydronapththol[1.2-d]thiazol-2-yl)-2-(3,4-dimethoxyphenyl)acetamide) used were obtained from Astra Zeneca and havebeen used previously as DGAT1 and DGT2 inhibitors, respectively (33). A thirdinhibitor, DGAT2-iJ (3-bromo-4-[2-fluoro-4-({4-oxo-2-[(2-pyridin-2-ylethyl)amino]1,3-thiazol-5(4H)-ylidene}methyl)phenoxy] benzonitrile) was obtained from JanssenResearch and Development UK, and has been used previously as a specific DGAT2inhibitor (5). All primers were purchased from Sigma-Aldrich.
RESULTS
A. Experiments using the brown adipocyte-derived cell line IMBAT-1In view of the large amount of preliminary work that was needed to establish theconditions under which the metabolic fluxes of interest could be measured, and theconcentrations of inhibitors required, we used a well-established brown adipocyte-derived cell line, IMBAT-1. This cell line has been well characterised, and has been shownto express all the proteins that are characteristic of brown adipocytes, especially UCP1(35). Their use also allowed us to verify the effects observed with specific DGAT1 andDGAT2 inhibitors through the efficient knockdown of the two proteins in these cells usingsiRNA.The main findings were validated using primary brown adipocytes (see below).
A.1 DGAT2 mRNA expression is preferentially induced during differentiationWe investigated the expression of DGATs across a panel of murine tissues. DGAT2mRNA was most highly expressed in BAT, and present at much lower levels in WAT, liver,intestine and mammary gland (Figure 1). DGAT1 mRNA was most highly expressed inthe intestine, followed by BAT, white adipose tissue and mammary gland. We thenstudied the profile of mRNA expression for both DGATs, compared with thedifferentiation marker aP2 during brown adipocyte differentiation. All three mRNAswere induced at day 2 of differentiation, but whereas DGAT1 mRNA was induced
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moderately during the first days of differentiation, levelling off thereafter and decliningon day 6, DGAT2 mRNA was induced 10-fold more strongly and continued to be inducedthroughout the period of differentiation, levelling off at day 6 (Figure 2). This timecourse of the expression of the two genes is the opposite to that previously describedduring the differentiation of white adipocytes, in which an initial peak in DGAT2expression (during initial differentiation with glucose as the main substrate) is overtakenby a sustained expression of DGAT1 mRNA during the latter stages of differentiation (35).
A.2     β3-adrenergic stimulation increases incorporation of de novo synthesised       
FA into TG and CO2We next measured the rates of labelling from U-14C-glucose into TG and CO2 in IMBAT-1 cells, and ascertained that they were linear during the 2h-period of the incubations (notshown). Stimulation of  IMBAT-1  cells with the β3-agonist CL316324 (CL)   for 2h before the start of incubations (by addition of U-14C-glucose label) resulted in a significantincrease in the incorporation of 14C-label from glucose into CO2 (Figure 3a). The rates ofCL-stimulated glucose incorporation were 22.8 ±1.3 and 50.6 ±1.0 pmol/h/106cells forTG-acyl and TG-glyceryl moieties, respectively. The incorporation into CO2 was 10.6± 1.4pmol/h/106cells, although this flux is not directly comparable to the previous two, as (i)14CO2 is generated both during lipogenesis and FA oxidation, and (ii) 14CO2 derived fromthe oxidation of de novo synthesised FA will have been diluted by unlabelled acyl moietieswithin the pre-existing TG pool. From the observation that 106 cells yield approximately10mg wet weight of cellular material, it is calculated that these rates are of the same orderof magnitude as the values reported for glucose uptake (~7.2 µm/h/g) and de novolipogenesis rates (~4.8 µm/h/g) in cold-acclimated rats in vivo (14,30).Etomoxir (an inhibitor of CPT1 which controls FA entry into mitochondria (36))inhibited CO2 labelling marginally under basal conditions (Figure 3) suggesting that, asexpected, in the absence of CL-stimulated TG lipolysis, CO2 labelling from glucose wasdue mostly to that generated in the course of lipogenesis. The increase in CO2 labellinginduced by CL was totally prevented by etomoxir (Figure 3a). As a result, it could becalculated that CL increased the rate of 14CO2 labelling due to CPT 1-dependent oxidationof de novo synthesised FA by approximately 4-fold (Fig 3a).
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Stimulation of the cells with CL also activated incorporation of label from U-14C-glucose into both parts of the TG molecule (glyceryl and acyl, Figures 3b and 3c,respectively) although differentially. Stimulation of U-14C-glucose incorporation into theacyl moieties of the TG molecule was consistently significantly higher (2-fold) than thatinto the glyceryl moiety of TG (50%) indicating that, whereas increased glucose uptakeby the cells by CL may have been a common contributor towards the increased labellingof TG from glucose (25), de novo lipogenesis was stimulated independently of, and to ahigher extent than, the pathway leading from glucose to triose phosphates (the lastcommon intermediates of glycerol-3-P and FA formation). Etomoxir did not affectincorporation of glucose into TG-acyl or TG-glyceryl moieties, confirming that its actionis specific to the inhibition of FA oxidation.
A.3 CL-stimulation of glucose incorporation into TG-FA and their oxidation is
ATGL-dependentTo test the possible role of TG synthesis and hydrolysis in the provision of glucose-derived FA for oxidation, we tested the effects of inhibition of TG hydrolysis, usingAtglistatin (a specific inhibitor of adipose triglyceride lipase, ATGL) and the non-specificlipase inhibitor tetrahydrolipstatin (THL). Both inhibitors prevented all the effects of CLtreatment on CO2 and TG labelling from U-14C-glucose without affecting basal rates(Figure 4). CL-stimulation of the incorporation of glucose into both acyl and glycerylmoieties of TG was totally prevented by ATGL. This indicated that a metabolite generatedby TG lipolysis activates one or more steps in the pathways leading from glucose to TGsynthesis, and occurs independently of the interruption of the provision of FA foroxidation as a result of the inhibition of TG hydrolysis. This positive feedback on TGsynthesis supports previous observations that TG lipolysis generates signallingmolecules that affect lipogenic fluxes (37-39).
A.4 Oxidation of de novo synthesised FA is DGAT2-dependentIn view of the preferential activation of the esterification of de novo synthesised FAinto TAG labelled from glucose, we studied the possibility that DGAT1 and DGAT2 may
have different roles in the esterification of newly synthesised FA into TG after β3-stimulation of IMBAT-1 cells. We used three compounds which have previously been
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well-characterised as specific inhibitors of the two DGATs. Compound DGAT1-iB waspreviously used (1,33,40,41) as a highly specific inhibitor of DGAT1; Compound DGAT2-
iC (see methods) was used in (1) as a selective inhibitor of DGAT2 at lowerconcentrations; and compound DGAT2-iJ was developed and used as a highly specificinhibitor of DGAT2 ((5); see Methods). As these compounds have been developed asinhibitors of the human enzymes, we performed dose-response studies to ascertain thatthey were effective inhibitors of TG synthesis in IMBAT-1 cells at concentrations thatwere not deleterious to cell viability. The concentrations required for each compound toinhibit incorporation of U-14C-glucose into the glyceryl or acyl moieties of TG (not shown)were similar to those found to be effective in HepG2 cells and on the recombinant humanenzymes (1,5,33). In the same experiments, we quantified cell viability, as judged by MTTmitochondrial viability assays, at the end of the 2h incubations. Thereafter, the effects ofDGAT1 or DGAT2 inhibition were investigated in detail, using single concentrations ofeach compound (see Legends to Figures) that gave significant inhibitory effects but withthe retention of full cell viability.Both the DGAT2 inhibitors tested (DGAT2-iC and DGAT2-iJ) resulted in a stronginhibition of the CL-stimulated incorporation of 14C-glucose into CO2 and TG-acyl groups(see Figure 5 a, b). By contrast, inhibition of DGAT1 (with DGAT1-iB ) did not affect eitherincorporation of label into 14CO2 (Fig 5a) or into TG-acyl groups (Fig 5b). Theseobservations suggest that DGAT2 activity is specialised for the esterification of de novosynthesised fatty acids into TG and subsequent mitochondrial oxidation of FA productsof TG lipoloysis. The validity of this conclusion is strengthened by the demonstration ofthe ability of the two structurally unrelated inhibitors of DGAT2 to produce identicaleffects. Both DGAT1 and DGAT2 inhibition decreased significantly the glucoseincorporation into the glyceride part of TG (Fig 5c), indicating that glycerol-3-P newlysynthesised from glucose is incorporated into DG pools that are used by either DGAT1 orDGAT2 as substrates.Importantly, the above observations were not altered qualitatively whenexperiments were conducted in the presence of added exogenous glycerol (0.75mM) andoleate (0.75mM in the presence of 0.25% albumin) to the medium (Figure 5d-f);onlyDGAT2 inhibition resulted in the loss of labelling from U-14C-glucose into TG-acylmoieties and CO2 (Figure 5d, e). Therefore, addition of exogenous oleate (or palmitate,not shown) did not affect the ability of DGAT2 inhibition specifically to affect the
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incorporation of de novo synthesised FA into TG (compare Figure 5b and 5e) or theformation of CO2 after CL treatment. These observations indicate that de novosynthesised FA are compartmentalised rapidly into a pool of TG which is not accessibleto exogenously added FA. Addition of exogenous glycerol and oleate appeared to increasethe effect of either DAGT1 or DGAT2 inhibition on glucose incorporation into TG-glyceryl,but did not affect the relative importance of the two enzymes in this process (compare
Figure 5c and f).To exclude the possibility that non-specific effects of enzyme inhibitors werecompromising the validity of our observations, we investigated the longer-term effects ofthe knockdown of the expression of either protein using individually targeted siRNAtreatment of IMBAT-1 cells. The effects of 72h siRNA treatment on mRNA expression ofthe DGAT1 and DGAT2 are shown in Figure 6. A scrambled sequence was used in controlcells. Note that reliable quantification of protein expression was not possible using arange of commercially available antibodies (not shown). Similarly, DGAT activities couldnot be reliably quantified by available DGAT assays using the amounts of materialavailable.The data in Figure 7a show that knockdown of DGAT2 had a major inhibitoryeffect on the incorporation of label from U-14C-glucose into CO2 both under basal and CL-stimulated conditions, indicating that de novo synthesised FA need to be incorporatedinto TG by DGAT2 before they can undergo mitochondrial oxidation in IMBAT-1 cells.Importantly, knockdown of DGAT1 did not have this effect at all (Figure 7a). Therefore,these data are identical qualitatively and quantitatively to those obtained using therespective DGAT1 and DGAT2 inhibitors (Figure 5). Knockdown of DGAT2 also had alarge inhibitory effect on the incorporation of glucose into TG (Figure 7b).Saponification of the lipid fraction confirmed the preferential stimulus of glucoseincorporation into the acyl moieties of TG, and showed that DGAT2 knockdown had largeinhibitor effects on the incorporation of label from U-14C-glucose into both TG-acyl andTG-glyceryl moieties under both basal and CL-stimulated conditions (Figure 7e, f).Therefore, effects of longer-term DGAT2 down-regulation with siRNA treatment on theformation of TG-acyl moieties, and their subsequent use for 14CO2 were quantitativelysimilar to those observed after short-term inhibition (Figure 5). By contrast, there wasno effect on glucose incorporation onto TG-acyl when DGAT1 was knocked down (Figure
7d), and much smaller effects than those achieved by DGAT2 knockdown on
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incorporation of glucose into TG-glyceryl (Figure 7c). These observations confirm thatDGAT2 is specialised for the channelling of de novo synthesised fatty acids towardsoxidation (to CO2) initially through their incorporation into a distinct pool of TG, followedby lipolysis.DGAT1 knockdown was completely ineffective in altering 14C-glucoseincorporation into TG-acyl, and had a smaller effect on incorporation into TG-glycerylmoieties than that observed after DGAT2 knockdown. Therefore, these data provideevidence that, in cells subjected to longer-term downregulation of either DGAT isoform,endogenously synthesised glycerol-3-P is preferentially used, to a considerable extent, tosynthesise a distinct pool of DG that acts as a substrate for DGAT2 (compare Figures 7cand 7e).
A.5 DGAT2 knockdown attenuates the CL-mediated induction of UCP1 mRNA
expressionIn view of the observed close association between DGAT2 down-regulation andmetabolism of de novo synthesised FA, we investigated whether long-term down-regulation of DGAT2 or DGAT1 is accompanied by changes of lipogenic gene expression.We measured the mRNA expression (before and after CL treatment) of UCP1 and ofseveral genes which are involved in the pathways leading from glucose to TG synthesisand CO2 formation (Figure 8). Incubation of the cells with CL for 2h increased theexpression of UCP1 mRNA four-fold in IMBAT-1 cells (as observed previously in BAT in
vivo (42)); DGAT2 knockdown resulted in the halving of this increase whereas DGAT1knockdown had no effect (Figure 8). CL-treatment also resulted in a significantinduction of the mRNA expression of GPAT1; downregulation of either DGAT1 or DGAT2increased basal expression of GPAT1 mRNA, whereas there was no effect of DGAT1knockdown on GPAT4 expression. By contrast, both GPAT4 and Elvol6 mRNAexpressions were decreased specifically by DGAT2 siRNA treatment both under basal andCL-stimulated conditions. None of the other genes tested (including Elvol3, not shown)showed significant differences in mRNA expression levels after CL-stimulation orknockdown of either DGAT compared to control (scrambled) siRNA-treated cells.Therefore, knockdown of DGAT2 moderately but specifically affected the expressionof three genes that are central to elongation of de novo synthesised FA (Elvol6), FA
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esterification (GPAT4), and uncoupling of mitochondrial FA oxidation (UCP1) (3,43,44)indicating that it may play a central role in the maintenance of BAT function.
A.6 Direct oxidation of exogenously added oleate is very lowWe next compared the roles of DGAT1 and DGAT2 in determining the metabolism ofexogenously added, preformed fatty acids. We performed a series of experiments inwhich the normal concentration of unlabelled glucose was accompanied by glycerol (0.75mM) and oleate (0.75 mM in the presence of 0.25% albumin). We performed parallelexperiments in which we labelled either the glycerol (2-3H-glycerol) or oleate (1-14C-oleate). We also used U-14C-palmitate to verify that the effects observed with oleate couldbe replicated using a saturated FA; the results with palmitate (not shown) were identicalto those obtained with oleate.Contrary to the incorporation of de novo synthesised FA and glycerol-3-P derivedfrom U-14C-glucose, the labelling of TG from either exogenous glycerol or oleate were not
stimulated by CL, showing that the effects of the β3-agonist were specific to the stimulation of glucose metabolism and FA derived from it. Although exogenous 1-14C-oleate was very rapidly incorporated into TG (75 ± 9 nmol oleate/h/106 cells), nosignificant 14C-label above background was recovered in oxidation products (either CO2or acid-soluble metabolites, ASM). Thus, although we used specific activities of 1-14C-oleate (and U-14C-palmitate) to provide the same degree of overall cellular TG labellingas that achieved by U-14C-glucose, only minimal 14C-label was recovered in CO2 or ASMafter exposure to 1-14C-oleate even when incubations were extended to 8h after additionof label to eliminate the possibility of a time-lag (not shown). There are two conclusionsfrom these observations. Firstly, that exogenous FA are not oxidised directly to CO2 toany significant extent in IMBAT-1 cells, although they are rapidly incorporated into TG.Secondly, that the pool of TG into which exogenous oleate is esterified is distinct fromthat into which de novo synthesised FAs are esterified by DGAT2, since the latter do giverise to 14CO2 linearly over a 2h incubation period. This is consistent with the observationin A.4, above, that addition of exogenous oleate did not alter the pattern of fluxes of U-[14C]-glucose into TG-acyl or TG-glyceryl moieties. The simplest explanation for thesecombined observations is that exogenous (pre-formed) oleate is incorporated into aseparate, large pool of TG in which the specific activity of 1-14C-oleate is highly diluted,resulting in a low specific activity of TG-acyl groups, and thus in negligible labelling of the
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CO2 produced from the oxidation of its constituent FA after lipolysis. De novosynthesised fatty acids, which labelled total cellular TG to the same extent, appear to havebeen incorporated into a TG pool in which a much higher specific activity of the acylgroups was achieved, before their oxidation 14CO2 (which could be easily quantified).Therefore, this pool must be considerably smaller, and must turn over rapidly to give thelinear and immediate CO2 formation observed.These inferences were supported by the effects on exogenous 1-14C-oleateincorporation into TG after the inhibition of either DGAT1 (using DGAT1-iB) or DGAT2(using DGAT2-iJ). When added individually, each inhibitor affected only marginally theincorporation of exogenous 1-14C-oleate into TG. However, incubation of cellssimultaneously with both DGAT1-iB and DGAT2-iJ resulted in almost complete inhibitionof labelling of TG from exogenously added 1-14C-oleate (Figure 9a). Therefore, theesterification of FA derived from exogenous, pre-formed oleate (or palmitate, not shown)can be catalysed redundantly by either DGAT1 or DGAT2. Only the combined inhibitionof the two enzymes decreased esterification of exogenously added oleate into TGsignificantly (Figure 9a). This was entirely different from the ability of DGAT2 down-regulation specifically to inhibit TG-acyl labelling from glucose.Incorporation of 2-[3H]-glycerol into TG was maximally decreased by inhibitionof DGAT1 (Figure 9b). Although DGAT2 inhibition also moderately decreased 2-3H-glycerol incorporation into TG, this effect was much smaller than that of DGAT1inhibition, and combined DGAT2 and DGAT1 inhibition did not increase that achieved byDGAT1 inhibition alone. Therefore, exogenous glycerol is used for the synthesis of DGwhich serves preferentially as a substrate for DGAT1 (Figure 9b), whereas glucose-derived glycerol-3-P is used preferentially for the synthesis of DG used by DGAT2 (Figure
7e).
B. Experiments using mouse primary brown adipocytesHaving established the experimental conditions for the use of DGAT1 and DGAT2inhibitors, we wanted to validate the salient aspects of our observations using mouseprimary brown adipocytes. This enabled us to ascertain that the same conclusions areapplicable in a cell system closer to the physiological condition.
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B.1 CL stimulates etomoxir-sensitive glucose incorporation into CO2When primary brown adipocytes were treated with CL, the rate of CO2 formationfrom U-14C-glucose was increased by 5.5-fold (Fig 10). This was prevented by etomoxir,indicating that the glucose had to be converted into FA before it was oxidised. Thisinference was confirmed by the demonstration that incubation with TOFA (an inhibitorof lipogenesis at the ATP-citrate lyase step) also inhibited the etomoxir-sensitiveincorporation of glucose into CO2 (Figure 10). Although this scale of activation wassimilar to the 4-fold stimulation by CL of etomoxir-sensitive conversion of glucose intoCO2 observed in IMBAT-1 cells (see above), it occurred over a much lower background ofCO2 production in control primary cells. The absolute rates of incorporation of U-14C-glucose into CO2, TG-acyl and TG-glyceryl were 15.1 ± 1.1, 10.0 ± 1.5 and 10.0 ± 2.1nmol/h/106 cells, respectively. Therefore, primary brown adipocytes had very similarrates of glucose incorporation as IMBAT-1 cells (see above) but were more oxidative overthe experimental period used (1 -2 h), suggesting that the mobilization of the TG pool
feeding into oxidation is even more rapid than in IMBAT-1 cells.   Consequently, β3-adrenergic stimulation of the flux of glucose into CO2 and its prevention by inhibition ofDGAT2 (see below) was more pronounced in primary cells.
B.2 Inhibition of DGAT2 but not of DAGT1 prevents incorporation of U-14C from
glucose into TGGlucose incorporation into TG-acyl and TG-glyceryl moieties were both preventedby DGAT2 inhibition in primary brown adipocytes (Figure 10 a, b). Moreover, this effectwas mimicked by the inhibition of de novo FA synthesis with TOFA (an inhibitor of de
novo lipogenesis) indicating that DGAT2 utilises newly synthesised diglycerides and FAto form a distinct pool of TG. Inhibition of DGAT1 had no effect whatever onincorporation of labelled glucose into TG-acyl groups (as observed in IMBAT-1 cells).Although there was a tendency for the inhibition of DGAT1 to affect incorporation intoTG-glyceryl groups the effect was less than that shown by DGAT2 inhibition (as in IMABT-1 cells), and did not reach statistical significance (Figure 10 a).
B.3 Inhibition of DGAT2, but not DGAT1, prevents glucose conversion into CO2The CL-induced increase in CO2 production from glucose was entirely prevented byinhibition of DGAT2 (Figure 10c), confirming that, as in IMBAT-1 cells, the FA
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synthesised from glucose had to be incorporated into TG before they could be oxidised(subsequent to lipolysis). By contrast, inhibition of DGAT1 had no effect on the etomoxir-sensitive conversion of glucose into CO2. Therefore, the data obtained with primarybrown adipocytes fully confirmed our IMBAT-1 observations on the specialised role ofDGAT2 in channelling de novo synthesised FAs towards oxidation in brown adipocytes.The effect of DGAT2 was mimicked by inhibition of CPT1 with etomoxir and by theinhibition of de novo lipogenesis by TOFA (Figure 10c) confirming that DGAT2 actionlies on a pathway linking DNL to FA oxidation in brown adipocytes.
DiscussionGlucose is one of the two major substrates used by BAT. The high rate of glucoseuptake during cold exposure acts as a ‘glucose sink’ able to improve insulin sensitivityphysiologically during cold exposure (9,45) and after pharmacological activation aimedat increasing glucose utilization by BAT to regulate blood glucose in obesity and diabetes(12,45,46). Although BAT bioenergetics are centred around the uncoupled oxidation ofFA as the source of thermogenic capacity, there is a strong relationship between FAoxidation and glucose uptake in BAT (47); glucose-derived pyruvate makes only a minor
direct contribution towards mitochondrial electron transport chain activity. Thesimultaneous activation of glucose transport, de novo fatty acid synthesis and fatty acid
oxidation (FAO) in brown adipocytes by β-adrenergic stimulation (14,48,49) is consistent with the observations of increased expression of enzymes involved in FA-synthesis (e.g.FSN), FA-desaturation (SCD1) and FA–elongation (e.g. Elvol3, Elvol6) after cold-exposureor CL-treatment in vivo (13,23,37). However, the rationale for the oxidation of newlysynthesised FA has previously been questioned and considered paradoxical (9,10). It hasbeen proposed that the newly synthesised FA are not oxidised immediately, but arestored in LDs in anticipation of subsequent thermogenic activation (10,24,30).The present study has addressed this apparent paradox by showing that, in thebrown adipocytes (primary cells and IMBAT-1 cell line), glucose-derived FAs arespecifically channelled into a rapidly mobilised pool of TG, which is distinct from the bulkTG pool into which exogenous, preformed FA are esterified. This is evidenced by theDGAT2-dependence of the labelling of CO2 derived from de novo synthesised FA, but notthat derived from exogenous oleate, in spite of equivalent overall labelling of total cellularTG by both substrates. The ability of TOFA (an inhibitor of FA synthesis) to replicate the
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effects of DGAT2 inhibition supports the concept that channelling of de novo synthesisedFA towards oxidation occurs via DGAT2-mediated TG synthesis. This segregation of aglucose-derived, DGAT2-dependent synthesis of a distinct pool of TG enables the cell tooxidise de novo synthesised FA directly, and independently from FA derived exogenously.Therefore, DGAT2 acts as the link between increased glucose utilization and uncoupledmitochondrial FA oxidation, as part of a concerted response of this pathway to adrenergicstimulation in brown adipocytes (see Figure 11). Previous experiments performed in
vivo had found evidence for distinct pools of TG being used to channel FAs towardsoxidation or esterification (50,51) and for the dependence of the stereospecificdistribution ion cellular TG of de novo synthesised and exogenous FA (52,53). The currentobservations on the specialisation of TG formed via DGAT1 or DGAT2 provide amechanism through which these distinct TG pools could be achieved.When we tested this concept in primary brown adipocytes, we found that in thiscellular model too, DGAT2 (but not DGAT1) inhibition totally prevented incorporation ofglucose into TG acyl and TG-glyceryl moieties, and the formation of CO2 from de novosynthesised FA. Indeed, because primary brown adipocytes are more oxidative thanIMBAT-1 cells, the role of DGAT2 in mediating the channelling of glucose carbons towardsFA oxidation was even more apparent. Moreover, we demonstrated that the effect ofDGAT2 inhibition on these parameters could be mimicked by inhibition of de novolipogenesis with TOFA, thus showing the close link between DGAT2 action and utilizationof de novo synthesised FAs for TG synthesis and subsequent oxidation.The specialised role of DGAT2 in esterifying de novo synthesised FAs is similar tothat described originally in HepG2 cells (1,2). More recently, urokinase-typePlasminogen Activator (uPA) has been shown to stimulate TG synthesis from acetate, inparallel with increased de novo lipogenesis (DNL) and the specific induction of theexpression of DGAT2 (54). These observations suggest that this specialised function ofDGAT2 may be a ubiquitous function of this enzyme in different cell types, with metabolicoutcomes depending on tissue function, e.g. linking glycaemia to triglyceridaemia in theliver (2), and the channelling of glucose-derived FA towards rapid oxidation in BAT(present data).The ability of ATGL inhibition to prevent the CL-mediated stimulation of CO2formation from de novo synthesised FA derived from glucose would be expected to resultfrom the interruption of FA supply by inhibition of TG lipolysis. However, in addition,
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ATGL inhibition also prevented the stimulation of glucose incorporation into TG (bothglyceride and acyl moieties) indicating that a product of lipolysis activates glucosemetabolism by the cells through a positive feedback mechanism (Figure 10). Inhibitionof TG lipolysis is suggested to have interrupted this feedback activation of one or moresteps leading from glucose to the synthesis of glycerol-3-P, de novo FA synthesis andesterification into TG. This is consistent with previous observations that in Atgl -/- mice
BAT shows diminished glucose uptake  (55), and that ATGL expression is essential for β3-activation of DNL in BAT in vivo (37,55). Our data suggest that in IMBAT-1 cells DNL isstimulated to a greater extent than incorporation of glucose-derived glyceryl moietiesinto TG; therefore, positive feedback activation of DNL may occur partly independentlyof triose-phosphate formation. The importance of ATGL in the provision of ligands for the
positive feedback-activation of PPARα target gene activation is well-established (56).  A proportion of the CO2 labelling from U-14C-glucose arises duringdecarboxylation of pyruvate and the direct oxidation of the resulting acetyl-CoA throughthe TCA cycle; this is known to make only a minor contribution towards thermogenesis(19). We distinguished between this direct oxidation of glucose and the CO2 derived fromFA oxidation by using etomoxir. This inhibitor of CPT1 decreased CO2 labelling onlymoderately in the absence of CL, but totally prevented the stimulation (4-fold in IMBAT-1 cells and 5.5-fold in primary adipocytes) mediated by CL indicating that the increasedformation of 14CO2 from glucose after CL stimulation was entirely due to increasedoxidation of de novo synthesised FA.. Importantly, the CL-mediated and etomoxir-sensitive stimulation of CO2 labelling from glucose was specifically prevented by down-regulation of DGAT2, but not of DGAT1. This indicated that (i) DNL and TG synthesisprecede the formation of CO2, and (ii) that DGAT2 is specifically involved in this pathway.Such sensitivity to DGAT2 down-regulation reinforces the conclusion that CO2 productiondoes not occur directly from the de novo synthesised FAs, but only subsequent to TGformation. Oxidation of exogenously added fatty acids is deduced to have been similarlyindirect in IMBAT-1 cells because detection of labelled CO2 or acid-soluble metabolite(ASM) formation was very low when cells were incubated with 1-14C-oleate or U-14C-palmitate, in spite of their very rapid labelling of cellular TG. This was also the case inprimary cells (not shown). As mentioned above, this can be explained if the added 14C-oleate was esterified into a large, pre-existing pool of TG within which its specific activity
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was highly diluted. This indirect route for FA oxidation has been described for severaltissues and cell types (57-60).It is evident that the specialisation of DGAT2 action for the esterification of de novosynthesised FA and nascent DG containing these FA provides a mechanism forchannelling glucose-derived FAs towards uncoupled FA oxidation upon adrenergic
stimulation. It is well-established that the activation of ATGL by β3-adrenergic agonism promotes TG turnover by simultaneously promoting glucose uptake and DNL, includingthe induction of proteins involved in DNL (37), thus providing substrates for DGAT2.Because of the importance of long-chain acyl-CoA synthase 1 (ACSL1) in channelling FA(whether supplied exogenously or synthesised de novo) towards mitochondrial β-oxidation and of GPAT4 in diverting FA towards TG synthesis (27,61), we consideredwhether the very low rates of labelling of 14CO2 from exogenously added 1-14C-oleate togenerate directly could have been due to a low expression of ACSL1 from IMBAT-1 cells.This possibility was excluded because we detected high levels of expression of ACSL1mRNA (Figure 8). In addition, adequate expression of ACSL1 can also be inferred fromthe observation that de novo synthesised FA were oxidised rapidly to CO2 simultaneouslywith TG labelling from glucose in a DGAT2-dependent manner. Both GPAT1 and GPAT4expressions were partly dependent on DGAT2 expression in IMBAT-1 cells (Figure 8b),and may play a major role in ensuring that both endogenously derived and exogenouslyadded FA are esterified to TG prior to oxidation.In IMBAT-1 cells, DGAT1 and DGAT2 act redundantly for the incorporation ofglucose-derived glycerol-3-P into TG, although less so after longer-term knockdown.However, exogenous glycerol is used preferentially for the formation of DG utilised byDGAT1, indicating that the two enzymes also have differential access to DG synthesisedfrom exogenous or endogenously synthesised glycerol-3-P. This compartmentalizationis different from the observations previously made on two liver systems (HepG2 cells (1)and murine liver (5)) in which DGAT2 is specialised for the incorporation of exogenousglycerol into TG. This difference in the handling of glycerol-3-P formed from exogenousglycerol may reflect the differences between the metabolism of TG in liver and BAT.Thus, lipolysis in BAT goes to completion (to glycerol and FA) whereas it is mostlyrestricted to the formation of DG and monoglyceride (MG) in the liver, e.g. in rat liver in
vivo (62,63) and in primary rat hepatocytes (64). Therefore, in BAT, the lipolysis-reesterification cycling occurs between TG and FA, whereas in the liver cycling occurs
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primarily between DG and TG, or MG and DG (64) without the release of glycerol. In theliver, DG is mostly used for the resynthesis of TG either for maintenance of cytosolic TGstores in lipid droplets, or incorporated into VLDL (1,2,65). The specialization of specificenzyme isoforms for the channelling of FA is increasingly being recognised (see (61,66)).In summary, all our data on primary brown adipocytes and a brown adipocytederived cell line indicate that the DGAT2-dependent pool of TG is distinct from that intowhich exogenous, preformed FA are esterified. As a result, newly synthesised FA aremade immediately available for mitochondrial oxidation in a DGAT2-dependent manner.By contrast, exogenous FA are esterified into a separate, larger, pre-existing pool of TG.
Assuming that this pool of TG is itself mobilised during β-adrenergic stimulation, this indicates that exogenous FA and de novo synthesised FA are esterified into separate TGpools before being oxidised. However, whereas DGAT2 is exclusively responsible for theformation of the TG pool specific for de novo synthesised FA, it also participates, togetherwith DGAT1, in the (re)esterification of exogenous FA into the larger pool of cellular TG.These data suggest that within the multilocular structure of BAT lipid droplets, a sub-population of droplets, originate specifically as a result of DGAT2 activity, enriched in de
novo synthesised FA, and preferentially mobilised to enable glucose to contributeimmediately towards thermogenesis. This is consistent with the previous observationthat, within a given cell, individual lipid droplets have differential access to the TGbiosynthetic machinery (67).The very high level of expression of DGAT2 mRNA in the tissue in vivo, and its largefold-induction and persistence during IMBAT-1 cell differentiation are indicative of theimportance of DGAT2 expression for BAT function. In this context, the 4-fold induction ofUCP1 in IMBAT-1 cells upon CL-stimulation is markedly blunted after knockdown ofDGAT2 expression, suggesting that DGAT2 expression is important for the maintenanceof the brown adipocyte phenotype. It is noteworthy that Dgat2-/- mice do not survivebeyond 12h after birth. This has been ascribed to defects in skin lipid synthesis, and theassociated dehydration (7). Our data raise the possibility that they may also be unable tothermoregulate normally. It is well-established that deficient thermogenesis results inincreased mortality in neonatal rodents (68) and that prevention of glucose uptake byBAT in vivo by down-regulation of mTORC2 results in hypothermia (16). Although it islikely that the contribution that glucose makes towards heat production in BAT is notfully developed in the neonate (owing to the lower rates of DNL in the tissue before
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weaning (14)) it would become more important as the pups switch to a highcarbohydrate diet (at 2 – 3 weeks of age) such that glucose- and DGAT2-dependent non-shivering thermogenesis post-weaning might become critical for survival. Moreover, therole of DGAT2 in enabling glucose utilization for BAT thermogenesis (and possibleglycaemic and body weight control) needs to be considered when developingpharmacological strategies aimed at using the modulation of BAT activation to controlglycaemia and triglyceridaemia in obesity and diabetes.
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LEGENDS TO FIGURES
Figure 1 DGAT1 and DGAT2 mRNA expression in mouse tissuesThe levels of mRNA expression of (a) DGAT1 and (b) DGAT2 were measured in themouse tissues indicated. Values are means (± SEM) for three separate determinations.
Figure 2 Expression of DGAT1, DGAT2 and aP2 during differentiation of
IMBAT-1 cells
IMBAT-1 cells were differentiated for 6 days (see Methods section). The fold-activation of DGAT1, DGAT2, and aP2 mRNA expression relative to that at day 0, duringsubsequent differentiation. The variances of input cDNA were normalised against thelevels of three housekeeping genes; L19, B-actin and 36B4. Values are means (±SEM) forthree separate determinations for separate cell preparations. Note different scale of y-axis for DGAT2. Where error bars are not shown, they lie within the symbols.
Figure 3 Etomoxir selectively prevents the increase in glucose-derived CO2
formation after  β3-adrenergic stimulation of IMBAT-1 cells, but not the increased 
incorporation into the glyceryl and acyl moieties of TGCells were incubated with CL for 2h, followed by a further incubation period of 2h,at the start of which U-14C-glucose label was added (at zero time) as described in theMethods section. Incorporation of label was measured into (a) CO2, and (b) glyceryl- and
(c) acyl-moieties of TG. Etomoxir (Etmox) was added 30 min before the addition of label.Data are means (± SEM) for three separate experiments, and are expressed with respectto paired controls, which are set at 100% for each experiment. Values that were
significantly statistically different (P ≤ 0.05) are indicated by * (vs control) or #(CL+Etomoxir vs CL).
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Figure 4   ATGL inhibition prevents β3-induced stimulation of U-14C-glucose
incorporation into TG and CO2.Cells were incubated with CL for 2h before addition of U-14C-glucose, andincorporation of label into (a) CO2 and (b) TG was measured during a further 2hincubation (see Methods). When Atglistatin (Astat) or THL were present, they wereadded at the same time as CL. Data are means (±SEM) for three separate experiments,and are expressed with respect to Control values which are set at 100% for each
experiment.  Values that were statistically significantly different (P˂0.05) are indicated by * (CL vs Control) and # (CL+THL or CL+Astat vs. CL).
Figure 5 Effect of DGAT1 and DGAT2 inhibition on the incorporation of U-14C
glucose into CO2 and TG after β3-agonist stimulation of IMBAT-1 cells. Cells were incubated with CL for 2h before the start of incubations by the additionof U-14C-glucose label). Inhibitors were added individually 30 min before the addition oflabel (see Methods section). Experiments were performed in the absence (a–c) orpresence (d–f) of oleate (0.75mM with 0.25% BSA) and glycerol (0.75mM). Incorporationof label from U-14C-glucose was measured for a 2h period into CO2 (a, d), TG-acyl moieties(b, e), and TG-glyceryl moieties (c, f). The concentrations of inhibitors used were: DGAT1-iB, 0.75 µM; DGAT2-iC, 50 µM, and DGAT2-iJ, 50 µM. Values are means (±SEM) for threeseparate experiments and are expressed with respect to values for Controls (set at 100%)to which no CL or inhibitors were added. Values that were statistical significantly
different (P˂0.05) are indicated by * (CL vs Control) and # (CL + inhibitors vs CL only). 
Figure 6 Effects of siRNA-mediated DGAT1- or DGAT2-knockdown on the
respective levels of mRNA expression of the two enzymesDifferentiated cells were treated for 72h with either control (scrambled, SC) siRNAor siRNA targeted towards DGAT1 (SiD1) or DGAT2 (SiD2) and the level of (a) DGAT1and (b) DGAT2 mRNA expression was measured. Values (n=3) are means (±SEM) for a
representative experiment. Values that were statistically significantly different (P˂0.05) from SC are indicated by an asterisk.
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Figure 7 Effects of siRNA-mediated DGAT1- or DGAT2-knockdown on the rates of
incorporation of U-14C-glucose into CO2 and TG in the presence or absence of β3-
adrenergic stimulation of IMBAT-1 cells.Differentiated cells were treated for 72h with either control (scrambled, SC) siRNAor siRNA (SiD) targeted towards DGAT1 (SiD1) or DGAT2 (SiD2) - see Methods section.Cells were incubated +/- CL for 2h, followed by the measurement of the incorporation oflabel from U-14C-glucose into (a) CO2, (b) total TG, and (c,e) TG-glyceryl and (d,f) TG-acylmoieties of TG. Data are means (±SEM) for three separate experiments and are expressedwith respect to Control values (which are set at 100%) for each experiment. Values that
are statistically significantly different (P˂0.05) are indicated by * (SC+CL or SiD vs SC)and # (SiD+CL vs SC+CL).
Figure 8 Effect of siRNA-mediated knockdown of DGAT1 and DGAT2 on the
expression of genes involved in pathways leading from glucose to TG-synthesis
and CO2 formationDifferentiated cells were treated for 72h with control siRNA (scrambled, SC) orsiRNA targeted against DGAT1 (SiD1) or DGAT2 (SiD2). mRNA determinations wereperformed on cells incubated for 2h either in the absence (-) or presence (+) of CL. Thevariances of input cDNA were normalised against the levels of three housekeeping genes;L19, B-actin and 36B4, and expressed relative to those of SC, which were set at 1.0. Valuesare means (±SEM) for three separate experiments. Values that were statistically
significantly different (P˂0.05) are indicated by * (vs SC) and # (vs SC+CL). ACC1, acetyl-CoA carboxylase 1; FASN, fatty acid synthase.
Figure 9 Effects of individual or combined inhibition of DGAT1 and DGAT2 on the
incorporation of added oleate or glycerol into TGCells were incubated with glucose, oleate and glycerol (see text forconcentrations). When present, CL was added 2h before the addition of label, either (a)1-14C-oleate or (b) 2-3H-glycerol. The inhibitors (DGAT1-iB to inhibit DGAT1, and DGAT2-
iJ, to inhibit DGAT2 specifically) were added 30 min before the addition of label. Values
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are means (±SEM) for three separate experiments. Values that are statisticallysignificantly different from those for Control (P<0.05) are indicated by an asterisk.
Figure 10 Effect of DGAT1 and DGAT2 inhibition on the incorporation of U-14C
glucose into CO2 and TG after β3-agonist stimulation of primary brown adipocytes Cells were incubated with CL for 2h before the start of incubations by the additionof U-14C-glucose label). Inhibitors were added individually 30 min before the addition oflabel (see Methods section). Experiments were performed in presence of oleate(0.75mM with 0.25% BSA) and glycerol (0.75mM). Incorporation of label from U-14C-glucose was measured for a 2h period into (a) TG-glyceryl moieties, (b) TG-acyl moietiesand (c) CO2. The concentrations of inhibitors used were: DGAT1-iB, 0.75 µM; DGAT2-iC,50 µM, and DGAT2-iJ, 50 µM. Values are means (±SEM) for three separate experimentsand are expressed with respect to values for Controls (set at 100%) to which no CL or
inhibitors were added. Values that were statistical significantly different (P˂0.05) are indicated by * (CL vs Control) and # (CL + inhibitors vs CL only).
Figure 11 Proposed pathways that link DGAT2 to de novo fatty acid synthesis and
thermogenesis in brown adipocytesFatty acids synthesised de novo from glucose (FA’’) are used to form a pool ofdiglyceride (DG’’) which is esterified with FA’’ by DGAT2 to form a distinct pool of
triglyceride (TG’’). Adrenergic (β3) stimulation simultaneously activates de novolipogenesis and TG lipolysis. A product of lipolysis activates the process of glucose
utilization for lipogenesis (DNL) upon stimulation of the cells by β3-agonists through a positive feedback mechanism which is interrupted by inhibition of ATGL. TG lipolysisprovides FA substrate for uncoupled mitochondrial oxidation. FA activate UCP1, the
expression of which is increased by β3-action. Glycerol-3-P synthesised from exogenous glycerol is used for the synthesis of a separate DG pool (DG’) which is used as a substratefor re/esterification preferentially by DGAT1, and to a lesser extent by DGAT2. Glycerol-3-P generated endogenously from glucose is used to form both DG’’ and DG’. ExogenousFA is not oxidised directly, but is re/esterified by DGAT1 or DGAT2 redundantlyinto/within a larger TG pool (TG’) before oxidation.
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